Earnings Call Summary | Gamida Cell(GMDA.US) Q4 2023 Earnings Conference
Earnings Call Summary | Gamida Cell(GMDA.US) Q4 2023 Earnings Conference
The following is a summary of the Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript:
以下是金美達電池有限公司(GMDA)2023年第四季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Gamida Cell reported its first year as a revenue-generating company in 2023, with net revenue of $1.1 million in Q4 2023 and a full-year net revenue of $1.8 million.
Full-year Cost of sales was $1.5 million, resulting in 18.5% gross margin.
R&D expenses decreased to $24.3 million in 2023 from $42.7 million in 2022 due to the company's transition into a commercial stage.
The net loss for 2023 was $63 million, a decrease from 2022's loss of $79.4 million.
Gamida Cell在2023年報告了其作爲創收公司的第一年,2023年第四季度淨收入爲110萬美元,全年淨收入爲180萬美元。
全年銷售成本爲150萬美元,毛利率爲18.5%。
由於公司過渡到商業階段,研發費用從2022年的4,270萬美元降至2023年的2430萬美元。
2023年的淨虧損爲6,300萬美元,較2022年的7,940萬美元虧損有所減少。
Business Progress:
業務進展:
Gamida Cell initiated strategic restructuring, converting $75 million of existing unsecured convertible senior note into equity with Highbridge Capital Management, which will own 100% of the outstanding equity in the newly reorganized company.
This move reduces Gamida Cell's debt by $75 million and trims the annual interest expense by $4.4 million.
The company plans to continue the commercialization of OMISIRGE and extend its relationships with transplant center partners to increase access to the drug.
Gamida Cell啓動了戰略重組,將現有的7500萬美元無抵押可轉換優先票據轉換爲Highbridge Capital Management的股權,後者將擁有這家新重組公司100%的已發行股權。
此舉使Gamida Cell的債務減少了7500萬美元,並將年度利息支出削減了440萬美元。
該公司計劃繼續將OMISIRGE商業化,並擴大與移植中心合作伙伴的關係,以增加獲得該藥物的機會。
More details: Gamida Cell IR
更多詳情: Gamida Cell IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。